The Science

    AntiMicrobial Peptide (AMP)

    AMP research is considered by many to have begun in the laboratory of Dr. Michael Zasloff at the National Institutes of Health. While working with a group of amphibians in the mid 1980s, Dr. Zasloff noted that these animals seemed to be less susceptible to infection than he expected. He determined that excretions from the skins of these animals possessed antimicrobial properties, and from these excretions he isolated linear peptides that he termed magainins (magen or magain is the Hebrew word for shield).

    Since Zasloff’s discovery, over 1,600 AMPs have been isolated and characterized from organisms ranging from humans to amphibians to insects to plants. Most of these are linear peptides, but there are some exceptions. The sequences of amino acids in these AMPs can vary substantially. For example, the human AMP LL-37 is very different from the magainins of amphibian origin. However, LL-37 is similar to AMPs found in other mammals.

    Ceragenin Technology – the Effective Solution

    Ceragenin compounds are a class of cholic-acid based compounds discovered by Professor Paul B. Savage, Ph.D. at Brigham Young University in Provo, Utah. Ceragenins are non-peptide functional mimics of endogenous antimicrobial peptides such as cathelicidin (LL-37) and the alpha and beta defensins. CSA BioTech has licensed the exclusive rights to the ceragenin compounds for most animal health and pharmaceutical applications, excluding ophthalmology applications. We are offering the ceragenin technology to leading medical device companies for sublicense in certain fields, and are actively engaged in joint development and sublicensing programs with numerous industry leaders. We are also independently developing certain ceragenin-coated medical devices and ceragenin-based pharmaceuticals.

    CSA BioTech’s ceragenin technology consists of formulations of novel, broad-spectrum antimicrobial compounds also known as ceragenins, cationic selective antimicrobials or CSAs. Ceragenins have shown excellent, rapid bactericidal, fungicidal and virucidal results against a wide variety of pathogens, including gram-positive and gram-negative bacteria, and even multi-drug resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Our LifeGuardTM coating technology uses the ceragenin compound CSA-13 as its active ingredient and is designed for use on medical devices to provide long-lasting antimicrobial protection far superior to existing alternatives. Further, CSA-13 has been shown in existing testing to effectively prevent the formation of biofilms, an attribute that no known existing antimicrobial product is capable of accomplishing.

    Leave a Reply